Longeveron

LGVN

Biotechnology · Healthcare

Price

$0.62

+0.01 (+1.40%)

Market Cap

$12.4M

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+829.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.9M (2021) → 17.6M (2025)

Longeveron is a small clinical-stage biotechnology company focused on developing cell therapies to treat aging-related and life-threatening diseases. Its lead product, Lomecel-B, is made from special cells called medicinal signaling cells (MSCs) sourced from the bone marrow of healthy young donors. The company is targeting conditions like Alzheimer's disease, aging frailty, and hypoplastic left heart syndrome, a serious heart defect in children.

Longeveron earns very little revenue today, as its therapies are still in clinical trials and not yet approved for commercial sale. It is based in Miami, Florida, and operates primarily in the United States. The company burns significantly more cash than it brings in, which is typical for early-stage biotech firms but creates real risk — it must keep raising money to fund research. The biggest near-term driver is whether clinical trial results for Lomecel-B are strong enough to support regulatory approval, which would be required before any meaningful revenue can be generated.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+4.5% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+44.1% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$12M/ year

↑ Rising (+48% vs prior year)

>1,000% of revenue

55.8x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

18.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~11 months

$16M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Longeveron is putting 1004% of revenue into R&D and that number is rising. That's 55.8x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

66.3%

Premium pricing power — 66.3% gross margin

Operating Margin

-1199.7%

Losing money on operations — -1199.7%

ROCE

-29.8%

Weak — -29.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-45.3%

Shrinking sales (-45.3% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-1544.7%

Burning cash (-1544.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial